IRIS MEDICINE
11 employees on LinkedIn · 3 known investors
Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.
Founders & leadership
MM
Megan MatthewsCo-founder & President
Investors · 3
Frequently asked questions
- What does IRIS MEDICINE do?
- Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.
- Who founded IRIS MEDICINE?
- IRIS MEDICINE was founded by Megan Matthews.
- Who are IRIS MEDICINE's investors?
- IRIS MEDICINE's investors include Venrock, UCB Ventures, PsyMed Ventures.